Who are iloprost nebuliser solution's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Uptravi, Remodulin, Flolan, Epalrestat,Mecobalamin, Inhaled Epoprostenol and phenylephrine, Fundyl.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/iloprost-nebuliser-solution.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

iloprost nebuliser solution — Competitive Intelligence Brief

iloprost nebuliser solution (iloprost nebuliser solution) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Prostacyclin analogue. Area: Cardiovascular.

phase 3 Prostacyclin analogue Prostacyclin receptor Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

iloprost nebuliser solution (iloprost nebuliser solution) — Shanghai Jiao Tong University School of Medicine. Iloprost is a prostacyclin analogue that acts as a vasodilator and inhibits platelet aggregation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
iloprost nebuliser solution TARGET	iloprost nebuliser solution	Shanghai Jiao Tong University School of Medicine	phase 3	Prostacyclin analogue	Prostacyclin receptor
Uptravi	SELEXIPAG	AstraZeneca	marketed	Prostacyclin Receptor Agonist [EPC]	Prostacyclin receptor	2015-01-01
Remodulin	TREPROSTINIL	United Therap	marketed	Prostacycline Vasodilator [EPC]	Prostacyclin receptor	2002-01-01
Flolan	EPOPROSTENOL	AstraZeneca	marketed	Prostacycline Vasodilator [EPC]	Prostacyclin receptor	1995-01-01
Epalrestat,Mecobalamin	Epalrestat,Mecobalamin	Xiangya Hospital of Central South University	marketed	Prostacyclin analog + Cobalamin derivative combination	Prostacyclin receptor (IP receptor) + Methylcobalamin-dependent enzymes
Inhaled Epoprostenol and phenylephrine	Inhaled Epoprostenol and phenylephrine	University Health Network, Toronto	marketed	Prostacyclin analog with alpha-1 adrenergic agonist	Prostacyclin receptor (IP receptor); alpha-1 adrenergic receptor
Fundyl	ENPROSTIL		marketed	enprostil	Prostacyclin receptor, Prostaglandin E2 receptor EP1 subtype, Prostaglandin E2 receptor EP3 subtype

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Prostacyclin analogue class)

Bayer · 1 drug in this class
Shanghai Jiao Tong University School of Medicine · 1 drug in this class
University of Arizona · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). iloprost nebuliser solution — Competitive Intelligence Brief. https://druglandscape.com/ci/iloprost-nebuliser-solution. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab